Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

161.34$-4.88 -2.94 %
At close       04:00 PM    

Stock Snapshot

166.22
Prev. Close
165.14
Open
30.24B
Market Cap
2.43M
Number of Shares
160.00
Day Low
165.93
Day High
161.34
50.34
P/E Ratio
-
Free Float in %
3.20
EPS 2021
18.67
Book Value per Share
13.08
Cash Flow per Share
Seagen Inc. (SGEN)
Seagen Inc. (SGEN) stock rallied over -2.94% intraday to trade at $161.34 share on NASDAQ. The stock opened with a fall of % at $165.14 and touched an intraday high of $165.93, declining 0.17% against the last close of $166.22. The stock went to a low of $160.00 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$149.98$151.51$152.40$148.00635,192
2021-09-03$156.57$152.22$157.01$152.1078,340,000
2021-09-02$159.79$157.89$161.38$156.3372,550,000
2021-09-01$165.56$159.41$166.57$157.74100,040,000
2021-08-31$170.62$167.60$170.89$165.9273,790,000
2021-08-30$166.81$168.60$168.92$165.4751,860,000
2021-08-27$167.61$166.81$171.43$166.4553,430,000
2021-08-26$170.50$168.94$172.50$168.9050,580,000
2021-08-25$167.36$169.82$170.08$164.5666,990,000
2021-08-24$165.84$167.94$168.00$164.5943,520,000
2021-08-23$159.99$165.56$166.44$158.9496,870,000
Seagen Inc.
21823 30th Drive SE
Bothell, WA 98021
United States

http://www.seagen.com
425 527 4000
Employees
2092
Sector
Healthcare
Sales or Revenue
2.38B
Industry
Biotechnology
5Y Sales Change
45.20
Fiscal Year Ends
2020-12-30

Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam